Jacob Mandel

Dr. Jacob Mandel

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSarthak Pati
Sarthak Pati
Ujjwal BaidUjjwal Baid
Ujjwal Baid
BEBrandon Edwards
Brandon Edwards
MSMicah Sheller
Micah Sheller
SWShih-Han Wang
Shih-Han Wang
Spyridon BakasSpyridon Bakas
Spyridon Bakas
Although machine learning (ML) has shown promise across disciplines, out-of-sample generalizability is concerning. This is currently addressed by sharing multi-site data, but such centralization is challenging/infeasible to scale due to various limitations. Federated ML (FL) provides an alternative paradigm for accurate and generalizable ML, by only sharing numerical model updates. Here we present the largest FL study to-date, involving data from 71 sites across 6 continents, to generate an automatic tumor boundary detector for the rare disease of glioblastoma, reporting the largest such dataset in the literature (n = 6, 314). We demonstrate a 33% delineation improvement for the surgically targetable tumor, and 23% for the complete tumor extent, over a publicly trained model. We anticipate our study to: 1) enable more healthcare studies informed by large diverse data, ensuring meaningful results for rare diseases and underrepresented populations, 2) facilitate further analyses for glioblastoma by releasing our consensus model, and 3) demonstrate the FL effectiveness at such scale and task-complexity as a paradigm shift for multi-site collaborations, alleviating the need for data-sharing.

13 January 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
AFAvi Fellner
Avi Fellner
CMChen Makranz
Chen Makranz
MLMichal Lotem
Michal Lotem
FBFelix Bokstein
Felix Bokstein
ATAlisa Taliansky
Alisa Taliansky
SYShlomit Yust-Katz
Shlomit Yust-Katz

1 October 2020 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
ZSZaid Soomro
Zaid Soomro
MYMichael Youssef
Michael Youssef
SYShlomit Yust-Katz
Shlomit Yust-Katz
AJAli Jalali
Ali Jalali
APAkash J. Patel
Akash J. Patel
JMJacob Mandel
Jacob Mandel
Paraneoplastic syndromes can commonly occur due to lung cancer, especially small cell lung cancer. Frequently paraneoplastic syndromes can precede the diagnosis of the neoplasm or present with limited stage disease. However, these syndromes can also occur at the time of recurrence or metastasis of disease. This review focuses on the epidemiology, pathogenesis, clinical features, and current management of the most common paraneoplastic syndromes encountered in patients with small cell lung cancer. Manifestations of paraneoplastic syndromes in small cell lung cancer include endocrine syndromes with secretion of excess hormones, and neurologic syndromes due to the production of antibodies causing an autoimmune condition. Recent advances have allowed for greater understanding of these syndromes and for the development of improved diagnostic as well as therapeutic tools. Awareness of paraneoplastic syndromes in small cell lung cancer can lead to an earlier diagnosis and recognition of both the condition and in some cases the disease potentially improving the overall survival and prognosis for patients. Further research examining effective methods to improve recovery from neurologic deficits in patients with a paraneoplastic neurologic illness is warranted.

19 May 2015 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
SYShlomit Yust-Katz
Shlomit Yust-Katz
JMJacob Mandel
Jacob Mandel
JWJimin Wu
Jimin Wu
YYYing Yuan
Ying Yuan
CWCourtney Webre
Courtney Webre
TATerri Armstrong
Terri Armstrong

31 July 2017 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
JMJacob Mandel
Jacob Mandel
SYShlomit Yust-Katz
Shlomit Yust-Katz
APAkash J Patel
Akash J Patel
DCDavid Cachia
David Cachia
DLDiane Liu
Diane Liu
JGJohn F. de Groot
John F. de Groot
Glioblastoma is the most common primary malignant brain tumor in adults, but effective therapies are lacking. With the scarcity of positive phase III trials, which are increasing in cost, we examined the ability of positive phase II trials to predict statistically significant improvement in clinical outcomes of phase III trials. A PubMed search was conducted to identify phase III clinical trials performed in the past 25 years for patients with newly diagnosed or recurrent glioblastoma. Trials were excluded if they did not examine an investigational chemotherapy or agent, if they were stopped early owing to toxicity, if they lacked prior phase II studies, or if a prior phase II study was negative. Seven phase III clinical trials in newly diagnosed glioblastoma and 4 phase III clinical trials in recurrent glioblastoma met the inclusion criteria. Only 1 (9%) phase III study documented an improvement in overall survival and changed the standard of care. The high failure rate of phase III trials demonstrates the urgent need to increase the reliability of phase II trials of treatments for glioblastoma. Strategies such as the use of adaptive trial designs, Bayesian statistics, biomarkers, volumetric imaging, and mathematical modeling warrant testing. Additionally, it is critical to increase our expectations of phase II trials so that positive findings increase the probability that a phase III trial will be successful.

29 August 2014 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
JMJacob Mandel
Jacob Mandel
SYShlomit Yust-Katz
Shlomit Yust-Katz
DCDavid Cachia
David Cachia
JWJimin Wu
Jimin Wu
DLDiane Liu
Diane Liu
MGMark R. Gilbert
Mark R. Gilbert